- United Kingdom
- United States
- Switzerland
- Germany
- Series A
- Series B
- Growth
- Biotechnology
- Life Sciences
Syncona Partners is a leading investor in cell and gene therapy companies, as well as other biotech ventures, with a focus on turning groundbreaking scientific discoveries into global leaders. The firm invests in companies from Series A to growth stages, providing the capital and operational support needed to navigate the complexities of the biotech industry. Syncona’s portfolio companies are backed by deep expertise in the life sciences, aiming to improve human health with transformative therapies and innovations.
Investment Thesis
Manager's Experience
Team
Alessio D`addabbo-Analyst
Anastasia Prechistenskaya-People Partner
Annabel Clark-Head of Corporate Affairs and ESG
Ben Woolven-Business Strategy and Operations Partner
Caroline Horsford-Executive Assistant
Chris Hollowood-Chief Executive Officer
Christina Seed-Group Reporting and Treasury Manager
Edward Hodgkin-Managing Partner
Elisa Petris-Partner
Fiona Fernandez-Office Manager
Gemma Mountford-Executive Assistant
Gonzalo Garcia-Principal
Gwenaelle Pemberton-Regulatory Advisor
Harriet Gower Isaac-Chief People Officer
Helen D'Silva-Executive Assistant
Hitesh Thakrar-Executive Partner
John Tsai-Executive Partner
Kate Butler-Chief Financial Officer
Kenneth Galbraith-Chair of SIML and Executive Partner
Magdalena Jonikas-Partner
Marc Perkins-General Counsel
Melina Hoffmann-Associate
Michael Kyriakides-Principal
Nathaniel Dahan-Senior Associate
Nikki Padden-Finance Director
Launch
Nisha Sethi-Legal Counsel
Pierre Joffrin-Senior Associate
Raghd Rostom-Senior Associate
Richard Wooster-Executive Partner
Roel Bulthuis-Managing Partner
Head of Investments
Sarah Crabtree-Senior Legal Counsel
Sarah Qian-Associate
Stephen Molumby-Financial Planning and Analysis Manager
William Dutson-Group Accountant
Portfolio
Autolus Therapeutics
NightstaRx
Achilles Therapeutics
Bicycle Therapeutics
Mereo BioPharma
Cell Medica